Update on clinical role of tamoxifen

Current Opinion in Obstetrics and Gynecology

Volumn 15, Issue 1, 2003, Pages 13-23

  Benson, John R ^a   Pitsinis, Vassilis ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Chemoprevention; Hormonal therapies; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BRCA1 PROTEIN; BRCA2 PROTEIN; ESTROGEN; ESTROGEN RECEPTOR; LETROZOLE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG MECHANISM; ENDOMETRIUM CANCER; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ESTROGEN; RISK ASSESSMENT; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0037307684     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-200302000-00003     Document Type: Review

References (102)

1. Bentrem DJ, Jordan VC. Tamoxifen, raloxifene and the prevention of breast cancer. Minerva Endocrinol 2002; 27:127-139. •• Authoritative review of the current clinical development of chemopreventive agents with detailed accounts of the clinical and biological properties of tamoxifen and raloxifene. Pertinent discussions about duration of therapy, side effects and cross resistance. Detailed list of references.
2. Cole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI 46474. Br J Cancer 1971; 25:270-275.
3. Ward HWC. Anti-oestrogenic therapy for breast cancer: a trial of tamoxifen at low dose levels. BMJ 1973; 1:13-15.
4. O'Regan RM, Jordan VC. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol 2002; 3:207-214. •• Excellent account of the development of the SERM concept (with tamoxifen as the prototype) and the application of molecular technology in the design of newer agents for treatment and prevention of breast cancer with tissue specific effects and fewer unwanted side effects.
5. Assikis VJ, Jordan VC. Gynaecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynaecol Obstet 1995; 49:241-257.
6. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in post-menopausal women with breast cancer. N Engl J Med 1992; 326:852-856.
7. Kristensen B, Ejlertsen B, Dalgaard P, et al. Tamoxifen and bone metabolism in post-menopausal low-risk breast cancer patients: a randomised study. J Clin Oncol 1994; 12:992-997.
8. Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in post-menopausal women. Ann Intern Med 1991; 115:860-864.
9. Nabulsi AA, Folsom AR, White A, et al. Association of hormone replacement therapy with various cardiovascular risk factors in post-menopausal women. N Engl J Med 1993; 328:1069-1075.
10. Sacks FM, Walsh. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol 1994; 5:236-240.
11. Jordan VC. Antitumour effect of the anti-oestrogen ICI 46,474 (tamoxifen) in the dimethylbenzanthracene (DMBA)-induced rat mammary carcinoma model. J Steroid Biochem 1974; 5:354.
12. Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur J Cancer 1976; 12:419-425.
13. Lippman ME, Bolan G, Hiff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long term tissue culture. Cancer Res 1976; 36:4595-4601.
14. Jordan VC, Phelps E, Lingren JU. Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res Treat 1987; 10:31-35.
15. Kuiper GG, Enmark E, Pelto-Huikko M, et al. Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996; 93:5925-5930.
16. Paech K, Webb P, Kuiper GG, et al. Differential ligand activation of estrogen receptors ER alpha and ER beta at AP-1 sites. Science 1997; 277:1508-1510.
17. Jordan VC. Selective estrogen receptor modulation: a personal perspective. Cancer Res 2001; 61:5683-5687.
18. Bilimoria MM, Assikis VJ, Jordan VC. Should adjuvant tamoxifen be stopped at 5 years? Cancer J Sci Am 1996; 2:140-150.
19. Saarto T, Blomquist C, Enholm C. Antiatherogenic effects of adjuvant antiestrogens: a randomised trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in post-menopausal women with node positive breast cancer. J Clin Oncol 1996; 14:429-433.
20. McDonald CC, Alexander FE, Whyte BW, et al. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial . BMJ 1995; 311:977-980.
21. van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90:210-218.
22. Ernst T, Chang L, Cooray D, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 2002; 94:592-597.
23. Benson JR. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 2002; 94:1336-1337.
24. Fisher B, Costantino J, Redmond C, et al. A randomised clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors. N Engl J Med 1989; 320:479-484.
25. Fisher B, Constantino JP, Wickerman DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90:1371-1388.
26. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-1461.
27. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 360; 817:24. •• Important announcement on results of large chemoprevention trial with tamoxifen showing reduction in breast cancer risk with 18% projected mortality reduction at 10 years in high-risk women. Study emphasized that thromboembolic events (including pulmonary embolism) were a worrying aspect of tamoxifen therapy in the chemopreventive setting and questions whether the overall risk-benefit ratio justifies intervention.
28. Jordan VC. Tamoxifen for the treatment and prevention of breast cancer. Melville, New York: PRR Inc.; 1999. pp. 117-126.
29. De Muylder X, Neven P, van Belle Y. Tamoxifen and benign endometrial lesions. Eur J Cancer 1998; 34 (Suppl 4):S18-S19.
30. Carmichael PL, Ugwumadu AHN, Neven P, et al. Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 1996; 56:1475-1479.
31. Decensi A, Fontana V, Bruno S, et al. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996; 14:434-440.
32. Bergman L, Beelen MI, Gallee MP, et al. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group: assessment of liver and endometrial cancer risk following tamoxifen. Lancet 2000; 356:881-887.
33. Garuti G, Grossi F, Cellani F, et al. Hysteroscopic assessment of menopausal breast cancer patients taking tamoxifen: is there a bias from the mode of endometrial sampling in estimating morbidity? Breast Cancer Res Treat 2002; 72:245-253.
34. Love CD, Muir BB, Scrimgeaur JB, et al. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17:2050-2054.
35. Neven P, Vernaeve H. Guidelines for monitoring patients taking tamoxifen treatment. Drug Saf 2000; 22:1-11.
36. Juneja M, Jose R, Kekre AN. Tamoxifen-induced endometrial changes in postmenopausal women with breast carcinoma. Int J Gynaecol Obstet 2002; 76:279-284.
37. Vosse M, Renard F, Coibion M, et al. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynaecol 2002; 101:58-63. • Study examining endometrial lesions in 406 postmenopausal patients receiving tamoxifen compared with a control group of 823 women. Polyps were the most common pathology and all five endometrial cancers occurred after 3 years of tamoxifen use. Recommends baseline assessment with annual clinical examination after 3 years and prompt investigation of abnormal bleeding. Good discussion emphasizing lack of consensus on surveillance and quoting American College of Obstetricians and Gynaecologists recommending screening procedures 'at discretion of gynaecologist'.
38. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359:2131-2139. •• Long awaited preliminary results of the ATAC trial comparing anastrozole, tamoxifen or a combination thereof as adjuvant therapy in postmenopausal women with early breast cancer. Significant improvement in disease-free survival in anastrozole group, but no data yet on overall survival. Critical discussion on relative benefits of aromatase inhibitors over tamoxifen in adjuvant and chemopreventive setting, but conclusion that further follow up is necessary to make a full risk-benefit assessment.
39. Twombly R. Upstaging tamoxifen? New classes of drugs emerging for breast cancer. J Natl Cancer Inst 2002; 94:474-475. • Succinct and topical commentary on current trends and progress in standard endocrine treatments for breast cancer with potential new agents including aromatase inhibitors, SERMs and pure antiestrogens.
40. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in post-menopausal women: results from the MORE randomised trial. JAMA 1999; 281:2189-2197.
41. Benson JR. Recruitment of women into clinical trials. Lancet 2002; 359:164-166.
42. Gottardis MM, Jordan VC. The antitumor actions of keoxifene (raloxifene) and tamoxifen in the N-nitroso-N-methylurea induced rat mammary carcinoma model. Cancer Res 1987; 47:4020-4024.
43. Gradishar W, Glusman J, Lu Y, et al. Effects of high dose raloxifene in selected patients with advanced breast carcinoma. Cancer 2000; 88:2047-2053.
44. O'Regan RM, Gajdos C, Dardes RC, et al. Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice. J Natl Cancer Inst 2002; 94:274-283. •• Study addressing the issue of how to manage women who have completed 5 years of adjuvant tamoxifen therapy but remain at increased risk of recurrence. In a mouse model of short-term tamoxifen exposed breast cancer, raloxifene was ineffective in blocking the stimulatory effects of low-dose estrogen and may therefore not be appropriate as sequential therapy after tamoxifen.
45. Jordan VC, Glusman SE, Glusman MEL, et al. Incident primary breast cancers are reduced by raloxifene: integrated data from multi-center, double blind, randomised trials in 12 000 postmenopausal women [abstract]. Breast Cancer Res Treat 1998; 50:227.
46. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65:125-134.
47. Goss PE, Stausser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001; 19:881-894.
48. Lonning PE. Aromatase inhibitors and inactivators in breast cancer. BMJ 2001; 323:880-881.
49. Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant therapy. Clin Breast Cancer 2000; 1 (Suppl):S9-S14.
50. Geisler J, King N, Anker G, et al. In vivo inhibition of aromatisation by exemestane, a novel irreversible aromatase inhibitor in postmenopausal breast cancer patients. Clin Cancer Res 1998; 4:2089-2093.
51. Nabholtz A, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer therapy in postmenopausal women: results of a North American multicenter randomised trial. J Clin Oncol 2000; 18:3758-3767.
52. Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex Randomised Group Efficacy and Tolerability study. J Clin Oncol 2000; 18:3748-3757.
53. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19:2596-2606.
54. Benson JR. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 2002; 94:1336-1337.
55. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor in estrogen receptor positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group Trial. J Clin Oncol 1992; 10:1284-1291.
56. Goss PE, Strasser K. Tamoxifen resistant and refractory breast cancer. Drugs 2002; 62:957-966. • A comprehensive review of mechanisms of tamoxifen resistance and the potential value of aromatase inhibitors following acquisition of tamoxifen resistance.
57. Buzdar A, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996; 14:2000-2011.
58. Copur MS, Ledakis P, Bolton M, et al. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? [letter]. J Clin Oncol 2001; 19:2578.
59. Bagley CM, Rowbotham RK, et al. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? [letter]. J Clin Oncol 2001; 19:2579.
60. Costa SD. Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer? [letter]. J Clin Oncol 2001; 19:2580.
61. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomised trial. J Clin Oncol 2001; 19:3808-3816.
62. Harper-Wynne CL, Sacks NPM, Shenton K, et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol 2002; 20:1026-1035.
63. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7 alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]. estra-1,3,5,(10)-triene-3,17β-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001; 61:6739-6746.
64. Benson JR. Tamoxifen in early breast cancer. Lancet 1998; 352:404-405.
65. National Institutes of Health Consensus Development Corfference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93:979-984. •• Concise and pragmatic summary of current treatment recommendations for systemic adjuvant therapies (endocrine and chemotherapy) and postmastectomy radiotherapy by a 14-member panel of leading experts from the fields of oncology, radiology, surgery, pathology, public health and health policy.
66. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the treatment of primary breast cancer. J Clin Oncol 2001; 19:3817-3827.
67. Karnon J, Brown J. Tamoxifen plus chemotherapy versus tamoxifen alone as adjuvant therapies for node-positive postmenopausal women with early breast cancer: a Stochastic Economic Evaluation. Pharmacoeconomics 2002; 20:119-137.
68. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects and discontinuation in older women. J Clin Oncol 2001; 19:322-328.
69. Partridge AH, Wang PS, Winer EP, et al. Non-adherence with adjuvant tamoxifen therapy in women with early stage breast cancer [abstract]. Proc Am Soc Clin Oncol 2001; 20:238a.
70. Silliman R, Guadagnoli E, Rakowski W, et al. Adjuvant tamoxifen prescription in women 65 years and older with primary breast cancer. J Clin Oncol 2002; 20:2680-2688.
71. Fisher B, Dignam J, Bryant J, et al. Five versus more than tive years of tamoxifen for lymph node-negative breast cancer: updated findings of the National Surgical Adjuvant Breast and Bowel Project B-14 randomised trial. J Natl Cancer Inst 2001; 93:684-690. •• Large study confirming that more prolonged adjuvant tamoxifen therapy beyond 5 years confers no survival benefit and no statistically significant reduction in contralateral tumours following the second randomization. Further discussed in correspondence [72].
72. Benson JR. Five versus more than tive years of tamoxifen for lymph node-negative breast cancer: updated findings of the National Surgical Adjuvant Breast and Bowel Project B-14 randomised trial. J Natl Cancer Inst 2001; 93:1493-1494.
73. Swain S. Tamoxifen for patients with estrogen receptor-negative breast cancer. J Clin Oncol 2001; 19:93-97. •• Critical review of the evidence for benefits of tamoxifen in patients with truly estrogen receptor-negative tumours, examining primary breast cancer survival, contralateral breast cancer and beneficial estrogen agonist activities. Overall conclusion on tamoxifen not indicated for this subgroup, but a warning is given on misclassification of estrogen receptor status based on false negative immunohistochemistry results and failure of some assays to detect estrogen receptor beta.
74. Fisher B, Anderson S, Tan-Chiu E, et al. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001; 19:931-942.
75. Hutchins L, Green S, Ravdin P, et al. CMF versus CAF ± tamoxifen in highrisk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: Update of tamoxifen results [abstract]. Breast Cancer Res Treat 1999; 57:25.
76. Gogas J, Markopoulos CH, Skandalakis P, et al. Bilateral breast cancer. Am J Surg 1993; 59:733-735.
77. Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst 2001; 93:1008-1013. • Controversial retrospective cohort study (8981 patients) which failed to show a statistically significant reduction in incidence of contralateral breast cancer in patients treated with adjuvant tamoxifen with no chemotherapy. Also reported an increase in estrogen receptor-negative contralateral breast cancers but no survival differences. Inconsistent with other studies and questions raised about classification of estrogen receptor status.
78. Li CI, Malone KE, Weiss NS, Daling JR. Tamoxifen and contralateral breast cancer: the other side [correspondence]. J Natl Cancer Inst 2001; 93:1753.
79. Narod SA, Brunet JS, Ghadirian P, et al. Tamoxifen and risk of contralateral breast cancer in BRCA-1 and BRCA-2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356:1876-1881.
80. King M-C, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA-1 and BRCA-2. JAMA 2001; 286:2251-2256. • Important analysis of differential effects of tamoxifen as chemopreventive agents amongst women with BRCA-1 and BRCA-2 inherited mutations in the NSABP P-1 trial.
81. Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric 2002; 5:151-155. • A short study examining the effects of HRT in combination with tamoxifen therapy in breast cancer patients with menopausal symptoms (342 patients available for analysis). Hazard ratios for all types of hormone therapy (combined estrogenprogestogen, progestogen only or topical estrogen) and concurrent tamoxifen showed a nonsignificant decrease in risk of breast cancer recurrence associated with tamoxifen use, including a subset analysis of estrogen receptor-positive tumours. Larger prospective randomized trials are required to further address this issue of HRT use in breast cancer survivors.
82. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in use of hormone replacement therapy. Lancet 1996; 348:977-980.
83. Cuzik J, Baum M. Tamoxifen and contralateral breast cancer [letter]. Lancet 1985; 2:282.
84. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 1998; 362:93-97.
85. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 362:98-101.
86. Veronesi U, Maisonneuve P, Sacchini V, et al. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002; 359:122-124. • Follow-up study reinforcing earlier conclusions that tamoxifen does not significantly reduce rate of breast cancer in hysterectomized women. Suggestion that tamoxifen may partly negate increased risk of breast cancer associated with HRT use. This is further discussed in correspondence [87].
87. Benson JR. Tamoxifen for breast cancer in hysterectomised women [letter]. Lancet (in press).
88. Day R, Ganz P, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1. J Clin Oncol 1999; 17:2659-2669.
89. Jordan VC. Tamoxifen for the treatment and prevention of breast cancer. PRR Inc.: Melville, New York; 1999. pp. 225-234.
90. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BR CA-1 mutation carriers. J Natl Cancer Inst 1999; 91:1475-1479.
91. Vogel VG. Reducing the risk of breast cancer with tamoxifen in women at increased risk. J Clin Oncol 2001; 1987-92. • Development of a quantitative model to estimate breast cancer risk and hence apply risk reduction strategies which are in accordance with Food and Drug Administration directives on the use of tamoxifen to reduce incidence of breast cancer amongst women at increased risk.
92. Loman N, Johannsson O, Bendahl PO, et al. Steroid receptors in hereditary breast carcinomas associated with BRCA-1 or BRCA-2 mutations or unknown susceptibility genes. Cancer 1998; 83:310-319.
93. Rebbeck TR, Levin AM, Eisen A, et al. Reduction in breast cancer risk after bilateral prophylactic oophorectomy in BRCA-1 mutation carriers. J Natl Cancer Inst 1999; 91:1475-1479.
94. Gail MH, Brinton LA, Byar DP, et al. Projecting individualised probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:1879-1886.
95. National Cancer Institute. Breast cancer risk assessment tool. http://brca.nci.nih.gov.brc.
96. Hershman D, Sundararajan V, Jacobson JS, et al. Outcomes of tamoxifen chemoprevention for breast cancer in very high risk women: a cost-effectiveness analysis. J Clin Oncol 2002; 20:9-16.
97. Visscher DW, Padiyar N, Long D, et al. Immunohistologic analysis of estrogen receptor expression in breast carcinoma precursor lesions. Breast J 1998; 4:447-451.
98. Ottaviano YL, Issa JP, Parl FF, et al. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. Cancer Res 1994; 54:2552-2555.
99. Russo J, Ao X, Grill C, et al. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Res Treat 1999; 53:217-227.
100. Fabian CJ, Kimler BF. Beyond tamoxifen: new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. Ann N Y Acad Sci 2001; 952:44-45. •• An excellent and insightful account of new drug development for breast cancer prevention and methods for evaluating clinical efficacy using modulation of molecular markers and breast intraepithelial neoplasia as endpoints for response.
101. Fabian CJ. Breast cancer chemoprevention: beyond tamoxifen. Breast Cancer Res Treat 2001; 3:99-103.
102. Benson JR, Baum M. Changing philosophical perspectives in breast cancer. In: Tobias J, Houghton J, Henderson C, editors. Breast cancer: new horizons in research and treatment. London, Arnold Publishers; 2001. pp. 12-29.